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Introduction {#sec1}
============

Beneficial microbes are viable microorganisms that induce an advantage to health when ingested in sufficient amounts ([@bib31]). These bacteria can prompt a change in the diversity and metabolic activity of the gut microbiota ([@bib8]), can modulate innate and adaptive immune responses ([@bib32], [@bib44]), or can significantly improve epithelial barrier function ([@bib4], [@bib34]). Despite the reported beneficial influence of some microbes, there is still a scarceness of empirical data to substantiate the claims made my marketed microbial products. This poses a considerable challenge to consumers when selecting a suitable microbe as a potential therapeutic intervention to treat a given ailment. Thus there is an urgent need to expand the primary scientific literature that experimentally substantiates the proposed uses of beneficial microbes.

There is also a pressing need to develop efficient and faithful discovery platforms for identifying strains of beneficial microbes. The use of cultured mammalian intestinal epithelial cells for this purpose has many evident caveats, including the lack of complex tissue physiology, absence of specialized cell types, as well as the nonappearance of a mucous layer as a barrier to prevent direct contact of cells and microbes. On the other hand, screening for candidate beneficial microbes *in vivo* using the mouse model is prohibitively expensive with vast numbers of mice likely required for discovery and generation of statistically significant data. To address these challenges, our research group and others recently reported on conserved molecular mechanisms of host cell and microbe interactions in the intestines of both mice and *Drosophila* ([@bib21], [@bib26]). Indeed, the conserved nature of host cell and microbe interactions between mice and *Drosophila* has been widely reported, with examples including, but not limited to, juvenile growth during undernutrition ([@bib33], [@bib37]), restitutive signaling pathways that respond to bacterial infection ([@bib10], [@bib9], [@bib12], [@bib45]), microbiota-induced host gene expression ([@bib7], [@bib13]), the role of NADPH oxidases in epithelial response to mucosal dysbiosis ([@bib16], [@bib17]), and normal tissue development and stem cell response to gut microbes, which was recently comprehensively reviewed by Bonfini et al. ([@bib6]). In our studies, we showed that lactobacilli elicit cytoprotection in the intestines of mice and flies by a similar mechanism involving the activation of the cytoprotective Nrf2 pathway ([@bib20], [@bib35]). Owing to the transkingdom conservation of the functional elements that mediate the influences of beneficial microbes on host cells, we exploited and developed the use of the *Drosophila* model as an accessible and genetically tractable *in vivo* discovery platform for discovering beneficial bacteria.

The majority of promoted beneficial bacteria are lactic acid bacteria (LAB), with species from the *Lactobacillus* genus especially prevalent in marketed capsular and synbiotic preparations. Of the *Lactobacillus* species, *Lactobacillus casei* and *Lactobacillus rhamnosus* are arguably the most widely marketed beneficial bacteria, with investigative efforts focused on identifying the functional elements within specific strains of these species that mediate in their beneficial influences ([@bib19]). Indeed, our research group has been at the forefront of generating a substantial body of data describing the molecular mechanisms whereby *L. rhamnosus* GG elicits its beneficial influences on the host ([@bib3], [@bib2], [@bib5], [@bib22], [@bib41], [@bib40]). By comparison, few (if any) species from the *Lactococcus* genus have been experimentally demonstrated to exhibit beneficial influences on the host. Rather, lactococci are used in the dairy industry in the manufacture of fermented dairy products with *Lactococcus lactis* subsp. *lactis* and *Lactococcus lactis* subsp. *cremoris* commonly used as starter cultures in the production of cheese ([@bib36]). Importantly, because of its historical use in food fermentation, *L*. *lactis* has been provided the generally recognized as safe (GRAS) status by the US Food and Drug Administration ([@bib42]).

Herein, we describe the discovery of a strain of beneficial bacteria, namely, *L*. *lactis* subsp. *cremoris* ATCC 19257 (*L*. *lactis* subsp. *cremoris*) that we show confers potent cytoprotective and anti-inflammatory influences in the mouse intestine. We first discovered the cytoprotective properties of *L*. *lactis* subsp. *cremoris* in an *in vivo* screen using the *Drosophila* model that assess the potential beneficial influences of candidate beneficial bacteria. In assays measuring cytoprotection and gut permeability in the fly, *L*. *lactis* subsp. *cremoris* exhibited significantly stronger beneficial influences than any other tested bacteria. In the murine model, *L*. *lactis* subsp. *cremoris* protected mice from irradiation-induced intestinal tissue damage and lessened inhibited disease parameters induced by dextran sodium sulfate (DSS)-induced colitis. Importantly, *L*. *lactis* subsp. *cremoris* exhibited significantly stronger beneficial influences compared with *L. rhamnosus* GG, which is the most extensively studied beneficial microbe. Together, our data identify a beneficial bacterium, namely, *L*. *lactis* subsp. *cremoris* ATCC 19257 that exhibits potent anti-inflammatory and cytoprotective effects on the fly and mammalian intestine. We propose that the empirical data generated and reported in this article provide experimental basis for the use of *L*. *lactis* subsp. *cremoris* as a beneficial bacterium in the clinical environment.

Results {#sec2}
=======

*Lactococcus lactis* subsp. *cremoris* ATCC 19257 Confers Potent Cytoprotective Effects on the *Drosophila* Intestine in Response to Oxidative Challenge {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------------------------------------

We previously showed that a strain of *Lactobacillus plantarum* that we isolated from the midgut of *Drosophila* has cytoprotective influences against paraquat-induced oxidative challenge ([@bib20]). This was in contrast to feeding other commensal bacteria isolated from the fly intestine that did not exhibit cytoprotection in the same assay. We thus rationalized that *Drosophila* mortality following exposure to paraquat may be a faithful assay to identify bacteria that elicit beneficial influences on the host organism. To establish this notion, we assessed the survival in response to paraquat of 5-day-old germ-free adult *Drosophila* ([@bib25]) gnotobiotically mono-colonized with candidate LAB ([Table 1](#tbl1){ref-type="table"}). Of those tested, flies gnotobiotically mono-colonized with pure cultures of *L*. *lactis* subsp. *cremoris* ATCC 19257 were highly protected against oxidative injury as determined by the increased survival and significantly fewer apoptotic cells in the posterior midgut in response to paraquat ([Figures 1](#fig1){ref-type="fig"}A--1D). In addition, to determine the extent to which bacteria that have already been shown to elicit cytoprotection in mammalian models could also protect against paraquat toxicity assay in *Drosophila*, thereby showing that the fly assay is suitable for identifying probiotic bacteria that would potentially be effective in mammals, we gnotobiotically colonized *Drosophila* with the well-studied probiotic *L. rhamnosus* GG. We found that *L*. *rhamnosus* GG also elicited cytoprotection against paraquat toxicity in the fly model, albeit to a milder extent compared with *L*. *lactis* subsp. *cremoris* ([Figures 1](#fig1){ref-type="fig"}A--1D). Importantly, other LAB strains tested, including *Lactobacillus gasseri* ATCC 19992 and *Lactobacillus acidophilus* ATCC 4356, and those listed in [Table 1](#tbl1){ref-type="table"}, did not elicit cytoprotection in this assay, showing that the capacity of bacteria to elicit beneficial influences on the host is specific and variable within clades of bacterial taxa. We also assessed the capacity of the candidate bacterial strains to modulate gut permeability in adult *Drosophila*. This is done by an assay developed by [@bib30] that detects the amount of a colored dye (inert blue food dye) that translocates from the gut lumen to the open hemolymph of flies, which is the fluid that occupies the fly hemocoel and which is equivalent to blood in invertebrates. Specifically, 5-day-old germ-free male *w1118* flies were mono-colonized with pure cultures of candidate bacteria for 3 days. These flies were then exposed to paraquat diluted in blue food dye solution. Damage to intestinal tissue induced by paraquat results in loss of gut barrier integrity and translocation of the blue dye to the hemocoel, which is salient and visible under a light dissecting microscope ([Figure 1](#fig1){ref-type="fig"}E). Corroborating survival assays in [Figure 1](#fig1){ref-type="fig"}A, mono-association with *L*. *lactis* subsp. *cremoris* resulted in significantly fewer flies with blue dye translocation to the hemolymph than germ-free flies ([Figure 1](#fig1){ref-type="fig"}F). In addition, mono-association with *L*. *rhamnosus* GG resulted in significantly fewer flies with blue dye, albeit to a lesser extent compared with *L*. *lactis* subsp. *cremoris*, whereas flies mono-associated with non-cytoprotective bacteria could not significantly inhibit blue dye translocation to the hemolymph in the following paraquat exposure ([Figure 1](#fig1){ref-type="fig"}F). Together, these data demonstrate the first evidence for the beneficial properties of *L*. *lactis* subsp. *cremoris* ATCC 19257, beneficial properties that were markedly more efficacious in the *Drosophila* compared with *L*. *rhamnosus* GG or other LAB tested.Table 1List of Candidate Beneficial Bacteria Used to Mono-Associate Germ-free *Drosophila* and Screened for Their Capacity to Protect *Drosophila* against Paraquat-Induced Death or Paraquat-Induced Intestinal Damage in a "Smurf" Assay.Bacterial StrainAmerican Type Culture Collection (ATCC)*Lactobacillus acidophilus*ATCC 314*L. acidophilus*ATCC 4356*Lactobacillus fermentum*ATCC 9338*Lactobacillus gasseri*ATCC 19992*Lactobacillus leichmannii*ATCC 7830*Lactobacillus paracasei* subsp. *paracasei*BAA-52*Lactobacillus rhamnosus GG*ATCC 53103*L. rhamnosus*ATCC 7469*L. rhamnosus*ATCC 9595*L. rhamnosus*ATCC 53103*Lactococcus lactis*ATCC 11454*L. lactis*ATCC 19435*L. lactis*ATCC 49032*L. lactis* subsp. *cremoris*ATCC 19257[^2]Figure 1*Lactococcus lactis* Subsp. *Cremoris* ATCC 19257 Confers Potent Cytoprotective Effects in the *Drosophila* Intestine in Response to Oxidative Challenge(A) Graphical representation of experiments conducted to generate data presented in (B--D).(B) Relative survival of germ-free adult *Drosophila* gnotobiotically mono-colonized with the indicated lactic acid bacteria in response to paraquat challenge. Note only significantly enhanced survival of flies mono-associated with *L*. *lactis* subsp. *cremoris* ATCC 19257 (log rank test for germ-free (g-f) versus g-f + *L*. *lactis* subsp. *cremoris*, p ≤ 0.0006, n = 50), or mono-colonized with *Lactobacillus rhamnosus* GG (log rank test for g-f versus g-f + *L*. *rhamnosus* GG p ≤ 0.0202, n = 50).(C) TUNEL analysis of posterior midgut tissues dissected from *Drosophila* described in (A) at 24 h following paraquat challenge. Note the presence of TUNEL-positive cells in the Posterior 3 (P3) section of the midgut in response to paraquat.(D) Numeration of TUNEL-positive cells per midgut examined in (C). Data are represented as mean ± SEM. Nonparametric unpaired t test \*\*\*p \< 0.001, n = 10.(E) Example of adult *Drosophila* used to assess gut permeability via a Smurf assay. Germ-free adult *Drosophila* flies were gnotobiotically mono-colonized with the indicated lactic acid bacteria for 3 days. Thereafter, flies were subjected to a paraquat solution (spiked with inert blue food dye), which induces a leaky gut phenotype within 24--48 h. Flies that have a leaky gut are identified by exhibiting a visible blue color throughout their hemocoel within the body cavity.(F) Numeration of germ-free flies with visible blue color throughout their hemocoel as described in (D), in response to feeding of the indicated bacteria for 5 days, followed by being subjected to 17.5% paraquat solution and inert blue dye for up to 72 h. Note significantly fewer flies with visible blue color throughout their hemocoel following pretreatment with *L*. *lactis* subsp. *cremoris* ATCC 19257. Data are represented as mean ± SEM. Nonparametric unpaired t test \*\*\*p \< 0.001, n = 50.

*L. lactis* subsp. *cremoris* ATCC 19257 induces the activation of the Nrf2 signaling pathway in the *Drosophila* intestine by a mechanism that does not involve the detectable generation of reactive oxygen species (ROS).

We previously demonstrated that *L. plantarum* contact with cells induces ROS generation in *Drosophila* enterocytes ([@bib21]), and that cellular ROS enzymatically generated in response to contact with *L. plantarum* has salutary effects against exogenous insults to the intestinal epithelium via the activation of Nrf2-responsive cytoprotective genes ([@bib20]). These observations were recently corroborated by Lemaitre\'s group ([@bib18]). To determine whether *L*. *lactis* subsp. *cremoris* also induces the generation of ROS in the *Drosophila* midgut cells, thereby postulating a mechanism whereby *L*. *lactis* subsp. *cremoris* elicits cytoprotection, we used a class of ROS-sensitive hydrocyanine dyes (hereafter referred to as hydro-Cy3) to detect lactobacilli-induced ROS generation in larval midgut cells ([@bib23]). Intriguingly, whereas *L*. *plantarum* and *L*. *rhamnosus* GG induced high levels of ROS in larval midgut epithelial cells, *L*. *lactis* subsp. *cremoris* did not induce any detectable amounts of ROS generation in the same cells ([Figure 2](#fig2){ref-type="fig"}A). However, we also measured the capability of *L*. *lactis* subsp. *cremoris* to induce the activation of the cytoprotective Nrf2 pathway in flies using a GFP reporter fly bearing an antioxidant response element-dependent promoter (*gstD1*-GFP) that responds to Nrf2 nuclear translocation (known as CncC in *Drosophila*) ([@bib38]). We found that *L*. *lactis* subsp. *cremoris* is a potent activator of the CncC pathway to at least an equal extent as *L*. *plantarum* and *L*. *rhamnosus* GG ([Figure 2](#fig2){ref-type="fig"}A). Furthermore, we detected CncC-pathway-responsive gene transcript enrichment of *gstD1* in the midgut of third instar larvae mono-associated with *L*. *lactis* subsp. *cremoris* to levels that were significantly higher than those detected for *L*. *plantarum* and *L*. *rhamnosus* GG ([Figure 2](#fig2){ref-type="fig"}B). To corroborate these observations in mammalian cells, we tested the capacity of *L*. *lactis* subsp. *cremoris* to generate ROS in cultured enterocytes. Cells were loaded with the hydro-Cy3 dye and then overlaid with LAB. *L*. *rhamnosus* GG induced potent activation of ROS generation consistent with previous reports ([@bib21]), whereas there was no detectable ROS generation in cells overlaid with *L*. *lactis* subsp. *cremoris* ([Figure 2](#fig2){ref-type="fig"}C). However, similar to *L*. *rhamnosus* GG ([@bib20]), we detected transcript enrichment of Nrf2-responsive genes in the colon of germ-free mice colonized with *L*. *lactis* subsp. *cremoris* ([Figure 2](#fig2){ref-type="fig"}D). These data show that *L*. *lactis* subsp. *cremoris* may elicit beneficial influences on the host intestine by a different mechanism from that shown to function in the beneficial influences of *L*. *plantarum* and *L*. *rhamnosus* GG ([@bib20]).Figure 2*Lactococcus lactis* subsp. *cremoris* ATCC 19257 Induces the Activation of the Nrf2 Signaling Pathway in the *Drosophila* Intestine by a Mechanism that Does Not Involves the Detectable Generation of Reactive Oxygen Species within Enterocytes(A) Detection of ROS generation following the ingestion of indicated bacteria by germ-free third instar larvae for 1 h. ROS was detected by oxidation of the hydrocyanine ROS-sensitive dye that is present in the larval food. Shown also is the detection of the Nrf2-responsive anti-oxidant response element-dependent GFP expression in the distal midgut of germ-free gstD1-*gfp* 5-day-old adult *Drosophila* following ingestion of the indicated bacteria.(B) Detection of transcript enrichment in the midgut of the indicated CncC (Nrf2 in mammals) pathway-responsive genes in germ-free *Drosophila* mono-associated with the indicated bacteria for 4 h. Data are represented as mean ± SEM. Nonparametric unpaired t test \*\*p \< 0.01, n = 9 for all samples except for the *L*. *plantarum* dataset where n = 7.(C) Detection of ROS generation in cultured cells following contact with the indicated bacteria. Bacterial-induced ROS in cells contacted by the indicated bacteria for up to 30 min. Caco-2 cells seeded in a 96-well format were preloaded with 100  μM hydro-Cy3 and then contacted with 3 × 10^8^/100  μL viable bacteria for the indicated times. Cells were then washed three times with PBS before fluorometric analysis at 575 nm.(D) Detection of transcript enrichment of CncC pathway-responsive genes in the colonic epithelium of germ-free C57/B6 mice mono-associated with the indicated bacteria for 4 h. Data are represented as mean ± SEM. Nonparametric unpaired t test \*p\<0.05; \*\*p\<0.01; \*\*\*\*p\<0.0001, n = 5.

Ingestion of *Lactococcus lactis* subsp. *cremoris* Is Cytoprotective against Radiological Insult in Mice {#sec2.2}
---------------------------------------------------------------------------------------------------------

Identification of beneficial bacteria that dampen the symptoms of chronic inflammatory diseases of the intestinal tract is of intense investigative focus. We thus examined the extent to which *L*. *lactis* subsp. *cremoris* elicited cytoprotection in the intestine against radiological insult. Mice were fed either vehicle control, or 1 × 10^8^ colony-forming units (CFUs) of candidate bacterial strains that did or did not elicit cytoprotection in the *Drosophila* model, daily for 3 days. Thereafter the experimental groups were subjected to 12 Gy whole-body irradiation, whereupon murine weights were recorded daily. Feeding of vehicle control or lactobacilli strains that did not elicit cytoprotection in the *Drosophila* resulted in similar mortality rates with no statistically significant differences, whereas mice fed either *L*. *lactis* subsp. *cremoris* or *L*. *rhamnosus* GG exhibited significantly enhanced preservation of body weight and survival rates compared with vehicle control or non-protective strains ([Figures 3](#fig3){ref-type="fig"}A--3D). Indeed, *L*. *lactis* subsp. *cremoris* protected mice from irradiation-induced mortality to a significantly greater extent than *L*. *rhamnosus* GG. Intestinal tissue from select candidate strains that have shown similar levels of mortality were histologically examined at 24 h following insult with 12 Gy whole-body irradiation revealed that *L. lactis* subsp. *cremoris* and L. rhamnosus GG mice had significantly fewer apoptotic cells at the base of the colonic crypt compared with vehicle or other control strains of LAB ([Figures 3](#fig3){ref-type="fig"}E and 3F). Indeed, apoptotic TUNEL-positive were virtually undetectable at the base of the crypt of the experimental group of mice fed *L*. *lactis* subsp. *cremoris* and dosed with 12 Gy whole-body ([Figures 3](#fig3){ref-type="fig"}E and 3F). Together, these data show that *L*. *lactis* subsp. *cremoris* elicits potent cytoprotection from radiological damage in the murine colonic tissue.Figure 3Ingestion of *Lactococcus Lactis* Subsp. *cremoris* Is Cytoprotective Against Radiological Insult in Mice.A) Survival of 6-week-old C57BL/6 fed the indicated bacteria daily for 3 days followed 12 Gy irradiation insult. Note significantly enhanced survival of only mice treated before irradiation for three days with *L. lactis* subsp. *cremoris* ATCC 19257 (Log-Rank test for untreated vs. *L. lactis* subsp. cremoris treated, P=0.0006, n=5), or with *L. rhamnosus* GG (Log-Rank test for untreated vs. *L. rhamnosus* GG P=0.0202, n=5).(B) Weight of mice described in (A) measured daily after irradiation insult. Nonparametric unpaired t-test of bacterial *L. lactis* subsp. *cremoris* ATCC 19257 treated against untreated mice. \*\*=P\<0.01, \*\*\*=P\<0.001, \*\*\*\*=P\<0.0001, n=5.(C) Survival of 6-week-old C57BL/6 fed the indicated bacteria daily for 3 days followed 12 Gy irradiation insult. Analysis by Log-Rank test for untreated vs. bacterial treated revealed no significant differences in survival in mice treated *Lactobacillus gasseri* ATCC 19992, or with *Lactobacillus acidophilus* ATCC 4356.(D) Weight of mice described in (C) measured daily after irradiation insult. Nonparametric unpaired t-test of bacterial treated against untreated mice revealed no significant differences.(E) Detection of TUNEL-positive cells within colonic tissues harvested from mice described in (A-D). Scale bar size: 100µm.(F) Quantification of TUNEL-positive cells. Data are represented as mean +/- SEM. Nonparametric unpaired t-test \*\*\*p\<0.001, n=5.

*Lactococcus lactis* subsp. *cremoris* ATCC 19257 Protects the Murine Intestine from Dextran Sodium Sulfate-Induced Colitis {#sec2.3}
---------------------------------------------------------------------------------------------------------------------------

In addition to protection against radiological-induced intestinal damage, we used the DSS-induced gut injury and colitis model to assess the efficacy of *L. lactis* subsp. *cremoris* in modulating murine intestinal inflammation. As *L*. *lactis* subsp. *cremoris* and *L*. *rhamnosus* GG elicited potent cytoprotection against radiological damage, we focused our experimental efforts on these two beneficial bacteria. Mice were fed 1 × 10^8^ CFU *L*. *lactis* subsp. *cremoris*, *L*. *rhamnosus* GG, or vehicle control daily for 14 days. After 14 days, feeding of the bacteria ceased, and 4% DSS was included in the drinking water of the experimental groups. As expected, mice fed vehicle control responded to DSS by exhibiting considerable weight loss, presence of blood in fecal pellets, and high disease activity index (DAI) starting at 4 days following DSS ingestion ([Figures 4](#fig4){ref-type="fig"}A and 4B). Mice fed *L*. *rhamnosus* GG exhibited similar weight loss as vehicle control, and for the most part (except for day 7), exhibited no significant difference in DAI compared with vehicle control ([Figures 4](#fig4){ref-type="fig"}A and 4B). Strikingly, mice fed *L*. *lactis* subsp. *cremoris* exhibited significantly reduced DAI in response to DSS, with mice protected against DSS-induced colitis from day 6 onward ([Figures 4](#fig4){ref-type="fig"}A and 4B). Furthermore, mice fed *L*. *lactis* subsp. *cremoris* exhibited more rapid weight gain after the end of DSS treatment at day 7, i.e., at days 9 and 10 of the experiment ([Figure 4](#fig4){ref-type="fig"}A). Examination of colonic tissue at 10 days following onset of DSS treatment confirmed DAI observations in live animals, where *L*. *lactis* subsp. *cremoris-* (but not *L*. *rhamnosus* GG)-fed mice exhibited significantly preserved colon length and weight to length ratio compared with vehicle-fed control ([Figures 4](#fig4){ref-type="fig"}C and 4D). Furthermore *L*. *lactis* subsp. *cremoris*-fed mice exhibited markedly improved re-epithelialization and villi tissue morphology compared with vehicle-fed control or *Lactobacillus rhamnosus* GG (LGG) at day 10 of the experiment, with increased numbers of proliferative phospho-histone H3-positive cells, a marker for cell proliferation detectable in intestinal mucosa ([Figures 4](#fig4){ref-type="fig"}E and 4F). Finally, we measured the numbers of myeloperoxidase (MPO)-positive cells in the colonic submucosa in these mice. MPO is a major component of neutrophil granulocytes and thus is a faithful marker for the presence of neutrophils in the intestinal tissue. Neutrophils are recruited from general circulation to infected or injured intestinal tissue, including tissue injured in DSS-treated mice. *L*. *lactis* subsp. *cremoris*-fed mice exhibited significantly fewer MPO-positive cells in the colonic submucosa compared with vehicle-fed control or LGG-fed mice at day 10 of the experiment, indicating that inflammation and restitution occurred faster in *L*. *lactis* subsp. *cremoris*-fed mice ([Figures 4](#fig4){ref-type="fig"}G and 4H). Together, these data show that *L*. *lactis* subsp. *cremoris* potently dampened outward disease symptoms and intestinal tissue damage induced by a DSS gut injury and colitis model in mice.Figure 4*Lactococcus lactis* subsp. *cremoris* ATCC 19257 Protects the Murine Intestine from Dextran Sodium Sulfate (DSS)-Induced Colitis(A) Groups of five 6-week-old male C57/B6 mice were administered either 1 × 10^8^ CFU total *Lactococcus lactis* subsp. *cremoris* ATCC 19257, or *Lactobacillus rhamnosus* GG, or vehicle control for 14 days. Feeding of bacteria was ceased before 4% DSS being included in the drinking water (day 0) for 7 days in the indicated groups. Control groups of bacteria-fed mice were subjected to regular water. Measurement of weight loss in mice of the aforementioned groups following commencement of the inclusion of 4% DSS in the drinking water. Data are represented as mean ± SEM. Nonparametric unpaired t test \*p \< 0.05, n = 5.(B) Disease activity index (DAI) of mice described in (A). Nonparametric unpaired t test \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. n = 5.(C) Colon length of mice in (A) and (B) at day 10 following commencement of treatment with DSS. Data are represented as mean ± SEM. Nonparametric unpaired t test \*\*p \< 0.01, n = 5.(D) Colon weight to length ratio of mice in (A) and (B) at day 10 following commencement of treatment with DSS. Data are represented as mean ± SEM. Nonparametric unpaired t test \*\*p \< 0.01, n = 5.(E) Detection of phospho-histone-H3-positive cells in the colonic epithelium of indicated DSS-treated mice at day 10 following commencement of treatment with DSS.(F) Numeration of phospho-histone-H3-positive cells shown in (E). Data are represented as mean ± SEM. Nonparametric unpaired t test \*p \< 0.05, n = 5 per group.(G) Detection of myeloperoxidase (MPO)-expressing cells in the colonic tissue subepithelial compartments of colonic tissue at day 10 following commencement of treatment with DSS. White arrows point to cells stained positive with anti-Myeloperoxidase/MPO antibody that exhibit characteristic polymorphonuclear morphology of neutrophils.(H) Numeration of MPO-positive cells shown in (G). Data are represented as mean ± SEM. Nonparametric unpaired t test, with p values indicated for each comparison.

Discussion {#sec3}
==========

We identify *L*. *lactis* subsp. *cremoris* ATCC 19257 as a highly efficacious beneficial bacterium, which was successful in producing a desired and intended result of preserving gut tissue health in response to induced inflammation or injury. Importantly, the detected beneficial influences are a specific property of *L*. *lactis* subsp. *cremoris*, because other strains of LAB tested did not exhibit similar influences in the same injury models. In addition, *L*. *lactis* subsp. *cremoris* conferred significantly more efficacious influences in dampening intestinal inflammation in the DSS gut injury and colitis model compared with *L*. *rhamnosus* GG, which is a widely marketed and perhaps the most well-studied beneficial bacterium. To our knowledge, this is the first strain from the *Lactococcus* genus with demonstrated capacity to confer anti-inflammatory properties in the intestine subjected to DSS-induced colitis injury.

Current interventional therapies for intestinal inflammation include oral dosing of 5-aminosalicylic acid, antibiotics, corticosteroids, and immunomodulators and subcutaneous or intravenous administration of biologics ([@bib27]). However, the notion of using bacteria-based platforms in the clinical setting to treat intestinal inflammation is an increasingly recognized viable approach ([@bib43]). LAB, mainly from the *Lactobacill*us genus have been reported to suppress inflammation, strengthen gut epithelial barrier function, promote epithelial restitutional responses, and thus offer potential therapy for disorders of the gastrointestinal tract ([@bib14], [@bib29], [@bib39], [@bib28]). Importantly, our identification of *L*. *lactis* subsp. *cremoris* as a highly efficacious strain in ameliorating gut inflammation, at least in murine models, adds another microbe to the repertoire of beneficial bacteria to treat gut inflammation. Indeed, *L*. *lactis* subsp. *cremoris* has many key desirable features of beneficial bacteria. *L*. *lactis* strains are mostly non-colonizing, non-sporulating homolactate facultative anaerobes that have been used extensively in the fermentation of dairy products such as cheese and yoghurt for centuries and therefore fall under the GRAS status. These facts support the likelihood that potential use of *L*. *lactis* subsp. *cremoris* as a therapeutic bacterium to dampen intestinal inflammation would not be confounded by potential toxicological effects. Clearly, determining the extent to which *L. lactis* subsp. *cremoris* functions similarly in clinical settings as in the murine models is now a matter of investigative priority.

The discovery and demonstration of the highly efficacious nature of *L*. *lactis* subsp. *cremoris* in preserving tissue health in response to induced gut inflammation also has considerable implications in the search for beneficial microbes. Because other taxonomically related strains of *L*. *lactis* subsp. *cremoris* do not exhibit beneficial responses, it is likely that the beneficial influences of this stain are due to specific genetic elements and factors harbored within the bacteria. Comparative genomic analysis of taxonomically related beneficial and non-beneficial strains offers a powerful approach toward identifying these bacterial genetic elements that confer beneficial effects, which is an approach of intense current investigation within our research group. Moreover, identification of such genetic elements would also identify genetic targets within bacteria that may be the basis for a high-throughput screening platform to discover perhaps even more efficacious beneficial microbes. Indeed, employing multiple cell culture and invertebrate platforms to screen candidate beneficial microbes has the potential to generate cumulative evidence and rational for testing the efficacy of candidate beneficial microbes within *in vivo* mammalian models. Screening platforms would include testing if the microbe harbors a desired genetic element, has the capacity to induce nontoxic levels of ROS generation in cultured enterocytes ([@bib21]), or has the capacity to inhibit apoptosis in cultured cell ([@bib24]), to induce epithelial cell movement and would healing *in vitro* ([@bib3]), as well as to confer cytoprotection against oxidative challenge in *Drosophila* ([@bib20]).

Limitations of the Study {#sec3.1}
------------------------

The limitations of the current study are that the molecular mechanism whereby *L*. *lactis* subsp. *cremoris* confers anti-inflammatory influences remains enigmatic. Because we show in [Figure 2](#fig2){ref-type="fig"} that *L*. *lactis* subsp. *cremoris* ATCC 19257, unlike *L*. *rhamnosus* GG ([@bib21]), does not induce the cellular generation of ROS, we speculate that *L*. *lactis* subsp. *cremoris* may induce, or perhaps inhibit, the activation of a distinct set of pro-inflammatory downstream cell signaling pathways. The employment of methodology that measures transcript enrichment in tissues, such as RNA sequencing, or platforms that measure global protein enrichment, such as multiplex ELISA, will be valuable tools to elucidate downstream signaling events in this context. Furthermore, because *L*. *lactis* subsp. *cremoris* exhibits higher efficacy at ameliorating gut inflammation compared with *L*. *rhamnosus* GG, and many gut inflammatory states are associated with aggressive and dysregulated activation of innate and adaptive immunity ([@bib11], [@bib1], [@bib15]), it is also possible that *L*. *lactis* subsp. *cremoris* may act directly, or indirectly via enterocytes, on immune cell activity in the gut. At any rate, the efficacy of *L*. *lactis* subsp. *cremoris* at dampening inflammation caused by DSS-induced colitis is highly apparent and merits candidature for use as a bacterial therapy in the clinical environment as well as for the elucidation of the mechanistic mode of action.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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[^1]: Lead Contact

[^2]: Some of the listed bacteria were also used in assays to test for cytoprotection in murine gut injury assays.
